FEEDBACK
PLEASE WAIT ...
CLOSE
CLOSE

Manufacturer

Country

Certificates

FDA
Registration Date 12 Nov 2016
Share

Neulasta®

(0)

Medicine Pharmaceuticals Product Number : 55513-192-01

Hematopoietic

Drug Information

Generic
pegfilgrastim
NDC Code
55513-192-01
Drug Class
Granulocyte Colony-Stimulating Factor
Therapeutic Class
Hematopoietic
Dosage form
Solution
Route of Administration
SUBCUTANEOUS
Therapeutic Area
1.Neutropenia

Indication

Neulasta is used to prevent neutropenia, a lack of certain white blood cells caused by receiving chemotherapy. Neulasta is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Benefit

Neulasta® helps protect against the risk of infection and provides support through your chemotherapy cycle with just one injection. Neulasta® works like a natural protein within your body to signal the growth of new white blood cells, which helps protect against the risk of infection following chemotherapy.